With Trius near completion of its second phase III trial and with equity value of under 150 million (if you subtract cash on hand) is a true bargain. Tedizolid is a much better drug then Zyvox and likely the best drug in the MRSA space. Zyvox has over 1 billion in sales worldwide and Tsrx drug is cidal vs static for Zyvox needs to be taken only once daily, is less toxic and needs to be taking a shorter period of time. Truly a much better drug.
A partnership to market tedezolid in USA and Europe with a large upfront payment. If not the completion of the second phase III trial will cause a major move. Tedezolid is a superior drug to Zyvox which has 1.5 billion sales per year. I would say 2 year market cap could be 10x present value. This company is truly under the radar.